Latest news

Nov 13, 2024

Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update

Oct 22, 2024

Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis

Oct 01, 2024

Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference

X